Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2).
Maxence FicheuxLaure Peyro-Saint-PaulDorothée BalaynBlandine LecruxManon BrossierAntoine MorinAntoine LanotChloé PeronMarion BoulangerMarie BrionneFarzin BeyguiJean-Jacques ParientiThierry LobbedezC BéchadePublished in: BMJ open (2024)
ClinicalTrials.gov, NCT06045858; European Clinical Trial System, CT number 2023-507544-37-00.
Keyphrases
- atrial fibrillation
- peritoneal dialysis
- open label
- clinical trial
- study protocol
- phase ii
- phase iii
- end stage renal disease
- oral anticoagulants
- randomized controlled trial
- placebo controlled
- left atrial
- direct oral anticoagulants
- catheter ablation
- double blind
- left atrial appendage
- phase ii study
- image quality
- computed tomography
- dual energy
- heart failure
- contrast enhanced
- chronic kidney disease
- percutaneous coronary intervention
- magnetic resonance
- venous thromboembolism
- magnetic resonance imaging
- rectal cancer
- left ventricular